Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > “Conference call to discuss “A” corporate update”….

<< Previous

Bullboard Posts

Next >>

Comment by Azzak34on Apr 30, 2024 4:59pm

77 Views

Post# 36015899

RE:RE:RE:RE:“Conference call to discuss “A” corporate update”….

At least we're past sucking the straws buckster.

See, Peladawn was asking a question and Canadafan gave an answer. Kind of the way these sites should work, exchange of info and discussion.

What sort of petty little doosh would feel the need to post passive aggressive tripe for no reason? Your is 2 whole letters more than Ur. Could you force urself to spend the extra time to type out the remaining letters?

<< Previous

Bullboard Posts

Next >>

Quebecor achieves all Freedom Mobile acquisition commitments